The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Glucolipotoxicity, β-Cells, and Diabetes: The Emperor Has No Clothes
Open accessAbstract
Reduction of β-cell mass and function is central to the pathogenesis of type 2 diabetes. The terms glucotoxicity, lipotoxicity, and glucolipotoxicity are used to describe potentially responsible processes. The premise is that chronically elevated glucose levels are toxic to β-cells, that elevated lipid levels in the form of circulating free fatty acids (FFA) also have toxic effects, and that the combination of the two, glucolipotoxicity, is particularly harmful. Much work has shown that high concentrations of FFA can be very damaging to β-cells when used for in vitro experiments, and when infused in large amounts in humans and rodents they produce suppression of insulin secretion. The purpose of this Perspective is to raise doubts about whether the FFA levels found in real-life situations are ever high enough to cause problems. Evidence supporting the importance of glucotoxicity is strong because there is such a tight correlation between defective insulin secretion and rising glucose levels. However, there is virtually no convincing evidence that the alterations in FFA levels occurring during progression to diabetes are pathogenic. Thus, the terms lipotoxicity and glucolipotoxicity should be used with great caution, if at all, because evidence supporting their importance has not yet emerged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Martin, B. C., Warram, J. H., Krolewski, A. S., Soeldner, J. S., Kahn, C. R., Martin, B. C., & Bergman, R. N. (1992) · The Lancet · doi:10.1016/0140-6736(92)92814-v · Cited by 1,158 · cited 1×
“High FFA levels are considered to be a risk factor for the development of T2D (20); this makes sense because they are associated with and even contribute to insulin resistance, which places secretory demands on b-cells (21,22).”
BackgroundFive stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126
Self-citationGlucolipotoxicity: fuel excess and β-cell dysfunction
Poitout, V., & Robertson, R. P. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0023 · Cited by 1,092
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
What if Minkowski Had Been Ageusic? An Alternative Angle on Diabetes
McGarry, J. D. (1992) · Science · doi:10.1126/science.1439783 · Cited by 657
Excessive Insulin Response to Glucose in Obese Subjects as Measured by Immunochemical Assay
Karam, J. H., Grodsky, G. M., Forsham, P. H., & McWilliams, N. B. (1963) · Diabetes · doi:10.2337/diab.12.3.197 · Cited by 591
Metabolic Signaling in Fuel-Induced Insulin Secretion
Prentki, M., Matschinsky, F. M., & Madiraju, S. R. M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.018 · Cited by 548
Islet β cell mass in diabetes and how it relates to function, birth, and death
Weir, G. C., & Bonner‐Weir, S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12031 · Cited by 296
Self-citationPaolisso, G., Gambardella, A., Amato, L., Tortoriello, R., D'Amore, A., Varricchio, M., & D'Onofrio, F. (1995) · Diabetologia · doi:10.1007/bf00401761 · Cited by 217
Cited by
Why does obesity cause diabetes?
Klein, S., Gastaldelli, A., Yki-Järvinen, H., & Scherer, P. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.012 · Cited by 939
“…relevant because the plasma FFA concentrations achieved during those studies were much higher than the usual range found in people with obesity or type 2 diabetes, and the composition of the plasma FFA profile generated by hydrolysis of lipid emulsion triglycerides is not physiologic (Weir, 2020).”
BackgroundRecent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes
Lytrivi, M., Castell, A.-L., Poitout, V., & Cnop, M. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.09.016 · Cited by 408
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274
Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma
Chung, K. M., Singh, J., Lawres, L., Dorans, K. J., Garcia, C., Burkhardt, D. B., Robbins, R., Bhutkar, A., Cardone, R., Zhao, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.062 · Cited by 150
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Metadata
- Authors
- Weir, G. C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-01
- Volume
- 69
- Issue
- 3
- Pages
- 273-278
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2973075538
- Cited by
- 164
- References
- 13
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucolipotoxicity, β-Cells, and Diabetes: The Emperor Has No Clothes. https://app.cochat.ai/papers/10.2337/db19-0138
- The paper
- Weir, G. C. (2020). Glucolipotoxicity, β-Cells, and Diabetes: The Emperor Has No Clothes. Diabetes. https://doi.org/10.2337/db19-0138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.